Healthtech SaaS Valuation Multiples 2026: From Pharma SaaS Premium to Telehealth Collapse
Healthtech SaaS in Q1 2026 spans a 15x multiple range in public markets: Veeva at 6.9x EV/Revenue and Doximity at 5.9-7.0x anchor the premium end, while Teladoc has compressed to 0.46x after a 94% decline from its 2021 peak of 8.1x. Private markets tell a separate story — R1 RCM was taken private at 14.3x trailing EBITDA, and the 2025 digital-health IPO class (Hinge Health, Omada) priced at 6.5-7.7x revenue, resetting the floor from the 2021 euphoria.
Public Healthtech SaaS Comparables (Q1 2026)
The public healthtech cohort splits sharply by sub-segment. Pharma-vertical SaaS (Veeva), precision-medicine AI (Tempus), and high-margin clinician networks (Doximity) carry 6-7x EV/Revenue. RCM platforms (Waystar) sit in the 4-5x range on durable cash flows. Patient-engagement and analytics platforms (Phreesia, Health Catalyst, GoodRx) trade below 1.5x, compressed by growth deceleration. Telehealth (Teladoc) is at a 5-year low below 0.65x. The SaaS Capital Index sat at 5.5x in Q1 2026; healthtech leaders trade in line with that vertical-SaaS premium while distressed names trade far below it.
| Ticker | EV/Revenue | Revenue / ARR | Growth | NRR |
|---|---|---|---|---|
| VEEV | ~6.9x EV/Rev; P/S 10.25x | FY2026 $3.195B (+16% YoY); subscription $2.684B | +16% YoY (FY2026) | Not disclosed |
| DOCS | 5.93x (Apr 2026); 7.0x (Feb 2026) | LTM $626M; EBITDA $346M | Mid-teens YoY | Not disclosed |
| TEM | 6.1x (Apr 2026) | LTM $1.27B (Apr 2026) | High (LTM) | Not disclosed |
| WAY | 4.7x EV/Rev; 11.1x EV/EBITDA | LTM $1B; EBITDA $487M | +17% YoY (FY2026) | Not disclosed |
| HIMS | 3.4x EV/Rev; 25.8x EV/EBITDA | 2025 $2.35B (+59% YoY) | +59% YoY (2025) | Not disclosed |
| SDGR | 1.95x EV/Sales | LTM $256.95M | Flat / declining software | Not disclosed |
| GDRX | ~1.3x EV/Rev; 5.82x EV/EBITDA | LTM $796.85M | Flat | Not disclosed |
| PHR | 1.24x EV/Rev; P/S 1.1x | FY2026 $480.6M (+14% YoY) | +14% YoY | Not disclosed |
| PRVA | ~1.12x EV/Rev | 2025 LTM $2.12B | Strong; 2026 guide $2.35-2.45B | Not disclosed |
| HCAT | P/S 0.38x; sub-1x EV/Rev | FY2025 $311.1M | Slowing; Q1 2026 guide $68-70M | Not disclosed |
| TDOC | 0.46-0.64x EV/Rev | 2026 guide $2.48-2.58B; EV $1.60B | Flat / declining | Not disclosed |
Sources: Veeva IR FY2026 results; Phreesia FY2026 Business Wire release; Doximity multiples.vc (Feb-Apr 2026); Tempus AI multiples.vc (Apr 2026); Waystar Fierce Healthcare Q1 2026; Hims & Hers IR FY2025; GoodRx and Schrödinger stockanalysis.com statistics pages; Phreesia Simply Wall St; Health Catalyst Yahoo Finance; Privia GuruFocus EV/Revenue; Teladoc GuruFocus EV/Revenue (5-year history). NRR is not publicly disclosed by any company in this cohort.
Notable Private Healthtech Deals (2022-2025)
Private and pre-IPO healthtech transactions reveal two regimes. Strategic take-privates (R1 RCM at 14.3x trailing EBITDA, athenahealth at $17B) price on durable cash-flow quality and hospital-system entrenchment. Digital-health IPOs (Hinge Health at 7.7x, Omada at 6.5x) have reset to rational revenue multiples — well below the 2021 vintages (Hinge's own 2021 private valuation was $6.2B, 60% above its 2025 IPO price). The stale private marks of Lyra Health ($5.58B last round Jan 2022 vs $235M 2024 revenue) illustrate the un-marked correction still embedded in some portfolios.
| Company | Valuation | Round / Date | Revenue / ARR | Implied Multiple |
|---|---|---|---|---|
| R1 RCM | $8.9B EV | Take-private, Nov 2024 | Revenue-cycle management | 14.3x trailing EBITDA; 13.5x forward EBITDA |
| Tempus AI | $6.1B IPO valuation | IPO, Jun 2024 | 2023 rev $532M | ~11.5x trailing revenue at IPO |
| Maven Clinic | $1.7B post-money | Series F, Oct 2024 | ~$268M ARR (Sacra) | ~6.3-6.9x ARR |
| Hinge Health | $2.6B IPO valuation | IPO, May 2025 | 2024 rev $390M | 7.7x revenue; 60% below 2021 peak ($6.2B) |
| Omada Health | $1.1B IPO valuation | IPO, Jun 2025 | 2024 rev $170M (+38% YoY) | ~6.5x trailing revenue |
| athenahealth | $17B take-private | 2022 (benchmark comp) | Not disclosed (private) | Reference benchmark for cloud EHR M&A |
| Lyra Health | $5.58B (last mark Jan 2022, stale) | Series G, Jan 2022 | $235M 2024 revenue | ~24x at last mark — un-marked since 2022 |
Sources: R1 RCM TowerBrook press release (Nov 2024); Tempus AI IR IPO pricing (Jun 2024); Maven Clinic CNBC / Sacra profile (Oct 2024); Hinge Health CNBC IPO (May 2025); Omada Health CNBC IPO (Jun 2025); athenahealth Bain Capital announcement (2022); Lyra Health Fierce Healthcare (last round Jan 2022).
Three Valuation Dynamics Defining Healthtech SaaS in 2026
Veeva (VEEV) is the lone pure-play public pharma-vertical SaaS. FY2026 subscription revenue $2.684B (+17% YoY). GxP-compliance, audit-trail requirements, and 12-24 month integration cycles create a regulatory moat no horizontal SaaS competitor replicates. P/S sits near a 5-year low at 10.25x — the market no longer assigns a growth-stage premium, but the quality premium holds.
Teladoc (TDOC) hit a 5-year low of 0.5x EV/Revenue in Dec 2025, recovering fractionally to 0.46-0.64x by spring 2026. This compares to a peak of 8.1x in Dec 2021 — a 94% compression in four years. 2026 revenue guidance of $2.48-2.58B against a $1.60B enterprise value means the market assigns near-zero terminal value. Hims & Hers (HIMS) escapes this at 3.4x by running profitably ($128M net income in 2025) on DTC subscription growth.
Revenue cycle management commands a structural premium. Waystar (WAY) trades at 4.7x EV/Revenue and 11.1x EV/EBITDA with Q1 2026 net income of $43.3M and FY revenue +17%. R1 RCM's take-private at 14.3x trailing EBITDA (Nov 2024) signals that strategic buyers price hospital-embedded RCM at nearly 3x the revenue multiple of public telehealth — driven by annuity-like multi-year contracts and 95%+ switching costs.
Five Factors That Drive a Healthcare SaaS Premium
1. Vertical-SaaS premium of 25-30% over horizontal SaaS
Healthcare SaaS sits inside the vertical-SaaS premium bracket alongside finance, construction, and legal, commanding roughly 25-30% above horizontal-SaaS benchmarks according to Sofer Advisors. The SaaS Capital Index at 5.5x in Q1 2026 provides the baseline; Veeva at 6.9x and Doximity at 5.9-7.0x confirm the premium holds for category leaders. The premium is not automatic — Phreesia at 1.24x and Health Catalyst at sub-1x demonstrate that vertical positioning alone does not protect against growth deceleration.
2. HIPAA and regulatory moat
HIPAA compliance requirements, BAA agreements, and the cost of achieving and maintaining SOC 2 Type II plus HITRUST certifications create meaningful barriers that general-purpose SaaS vendors cannot circumvent with a price cut. For clinical SaaS companies like Tempus AI (now at 6.1x EV/Revenue), FDA SaMD authorisation and IRB data-use approvals layer additional regulatory moat on top of HIPAA. The compliance infrastructure is a fixed sunk cost that advantages incumbents in competitive bids.
3. EHR integration switching costs
FHIR/HL7 integration cycles run 12-24 months for enterprise health-system deployments. Once a vendor's data model is embedded in clinical workflows, replacement requires re-validating interfaces, retraining staff, and re-mapping data structures. Veeva actively deepens this moat by replatforming acquired products onto its Vault infrastructure. The athenahealth $17B take-private benchmark (Bain + Hellman & Friedman, 2022) reflects this dynamic: buyers paid a strategic premium knowing the installed base would not churn even under new ownership.
4. 10-year deployment lifecycles
Hospital EHR and RCM installs run multi-year contracts with 95%+ gross retention and typical 7-10 year replacement cycles. This translates into annuity-like revenue that justifies EBITDA-based pricing in private transactions. R1 RCM's 14.3x trailing EBITDA exit price reflects exactly this logic: strategic buyers model the long-duration cash flow and apply a lower discount rate than public equity markets do. Waystar's 11.1x EV/EBITDA at a 4.7x EV/Revenue multiple implies 43% EBITDA margins — structurally above horizontal SaaS.
5. FDA validation moat for clinical SaaS
Companies like Schrödinger and Tempus AI operate in regulated clinical environments where FDA SaMD clearance and IRB data access agreements serve as non-replicable moats. Tempus AI's EV/Revenue of 6.1x (April 2026) versus Schrödinger's 1.95x illustrates the market distinguishing between platforms with validated clinical AI workflows (Tempus, $1.27B LTM revenue) and computational-chemistry platforms where drug-discovery milestone revenue is lumpy and harder to model as recurring.
Five Factors That Discount Healthcare SaaS
1. Long sales cycles delay ARR recognition
Enterprise health-system deals run 9-18 months from first demo to signed contract, driven by multi-stakeholder approval processes (IT, compliance, clinical leadership, C-suite, payer contracting). This compresses near-term ARR growth visibility relative to PLG SaaS and increases CAC payback periods. For growth-multiple investors, the slow ramp makes health-system SaaS less attractive than developer-led or SMB-focused models at the same revenue run-rate.
2. Cyclical hospital IT budgets
Hospital operating margins compressed sharply in 2022-2024 due to labour shortages, wage inflation, and Medicaid rate pressures, deferring IT capex. Health Catalyst's FY2025 growth slowdown (Wells Fargo cut to Equal Weight) and Definitive Healthcare's guided revenue decline of 6-9% YoY in 2026 are direct consequences of hospital budget cycles that are outside any SaaS vendor's control. Payer-exposed platforms (Evolent, Privia) carry additional political risk around Medicare Advantage rate-setting.
3. Post-COVID telehealth re-rating
Teladoc peaked at 8.1x EV/Revenue in December 2021, driven by COVID-forced adoption of virtual care. By early 2026 that multiple had collapsed to 0.46x — a 94% compression — as in-person care normalised and payer reimbursement for routine telehealth became uncertain. The Teladoc-Livongo merger ($18.5B, 2020) compounded the damage: $3B+ of goodwill impairment followed, erasing the strategic rationale. The entire telehealth sub-segment carries the re-rating stigma.
4. FDA SaMD and clinical AI regulatory uncertainty
The FDA's Software as a Medical Device framework is still evolving in 2026. Payer reimbursement codes for AI-assisted clinical services — digital therapeutics, AI diagnostic tools, ambient documentation AI — lag product availability by 2-5 years. This creates revenue model uncertainty that suppresses valuation multiples for companies whose growth thesis depends on payer reimbursement. Schrödinger at 1.95x illustrates the market penalising milestone-dependent drug-discovery revenue even when the underlying software platform has genuine differentiation.
5. Down-round IPOs as a leading signal
Hinge Health's May 2025 IPO at $2.6B — 60% below its 2021 private valuation of $6.2B — established a public-market floor for the digital-health cohort. Omada Health IPO'd at $1.1B in June 2025, also a reset from higher private marks. These down-round IPOs signal that institutional investors are unwilling to pay 2021 multiples even for high-growth (Hinge: +50% Q1 YoY, Omada: +57% Q1 YoY) and profitable (Hinge: $17.1M Q1 net income) digital-health companies. Private investors with marks above the IPO prices are still carrying unrealised losses.
Healthcare SaaS Sub-Segment Multiple Map
Sub-segment selection is the primary valuation driver in healthcare SaaS. The spread from 0.46x (telehealth) to 6-7x (pharma-vertical, clinician network) reflects genuine differences in switching costs, contract structure, and regulatory moat — not just growth-rate variation.
| Sub-segment | Representative Companies | EV/Revenue Range | Multiple Tier |
|---|---|---|---|
| Pharma / Life-Sciences SaaS | Veeva (VEEV), IQVIA | 6-14x (Veeva 6.9x public; IQVIA not pure-SaaS) | Premium |
| Clinician Network / EHR | Doximity (DOCS), athenahealth (private), Epic (private) | 5-8x (Doximity 5.9-7.0x; athenahealth $17B take-private 2022) | Premium |
| Clinical Decision Support / Precision AI | Tempus AI (TEM), Schrödinger (SDGR) | 2-6x (Tempus 6.1x; SDGR 1.95x — milestone revenue drag) | Variable (AI-blend) |
| Revenue Cycle Management (RCM) | Waystar (WAY), R1 RCM (private) | 4-5x public EV/Rev; 11-14x EBITDA in take-privates | Moderate-Strong |
| Practice Management / Patient Intake | Phreesia (PHR), athenahealth | 1-2x (Phreesia 1.24x; peer average 2.1x) | Moderate (growth needed) |
| Patient Engagement / Commercial Intelligence | Doximity (DOCS), Definitive Healthcare (DH) | sub-2x to 7x (wide split: DH declining -6-9%; DOCS profitable) | Split |
| Telehealth / Virtual Care | Teladoc (TDOC), Hims & Hers (HIMS), Maven Clinic | 0.46-3.4x (TDOC 0.46x; HIMS 3.4x profitable outlier; Maven ~6.5x ARR private) | Depressed (except profitable DTC) |
| Mental Health / Digital Therapeutics | Lyra Health (private), Hinge Health (HNGE), Omada (OMDA) | 6.5-7.7x at 2025 IPOs; Lyra stale $5.58B mark (Jan 2022) | Variable (IPO reset in 2025) |
Sources: multiples.vc (Waystar, Doximity, Tempus); GuruFocus (Veeva, GoodRx, Teladoc, Privia); stockanalysis.com (Schrödinger, Hims, GoodRx); Simply Wall St (Phreesia); Sofer Advisors vertical-SaaS premium analysis; SaaS Capital Index Q1 2026 (5.5x baseline); Bain Capital athenahealth announcement; TowerBrook R1 RCM press release.
Founder of Digital Signet, an independent research firm publishing data-led pricing and decision tools. SaasValuationMultiple.com is sourced from Software Equity Group quarterly reports, public IPO comparables, SEC 10-K filings, and PitchBook excerpts. Multiples shown are reference ranges; for case-specific guidance consult an M&A advisor.